Plural N-c(=x)-x Groups Patents (Class 514/483)
-
Publication number: 20080103199Abstract: The present invention is a method for the treatment of Pervasive Developmental Disorders (PDDs) including; Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder (CDD), Rett's Disorder, and PDD-Not Otherwise Specified (PDD-NOS) comprising administering to a subject in need thereof a therapeutically effective amount of one or more carbamate compounds of Formula 1 and/or Formula 2 as herein defined and shown below. The present invention is directed to a method for the treatment of Pervasive Developmental Disorders (PDDs) including; Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder (CDD), Rett's Disorder, and PDD-Not Otherwise Specified (PDD-NOS), which includes mono-therapy and alternatively, co-therapy with at least one additional psychoactive medication.Type: ApplicationFiled: October 15, 2007Publication date: May 1, 2008Inventor: Magali HAAS
-
Publication number: 20080103198Abstract: This invention is directed to methods for providing otoprotection comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II), or a pharmaceutically acceptable salt or ester thereof: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).Type: ApplicationFiled: October 11, 2007Publication date: May 1, 2008Inventor: Magali HAAS
-
Publication number: 20080103127Abstract: The present invention is a method for the treatment of Disruptive Behavior Disorders including both Conduct Disorder and Oppositional Defiant Disorder comprising administering to a subject in need thereof a therapeutically effective amount of one or more carbamate compounds of Formula 1 and/or Formula 2 as herein defined and shown below. The present invention is directed to a method for the treatment of Disruptive Behavior Disorders including both Conduct Disorder and Oppositional Defiant Disorder, which includes mono-therapy and alternatively, co-therapy with at least one additional psychoactive medication.Type: ApplicationFiled: October 11, 2007Publication date: May 1, 2008Inventor: Magali HAAS
-
Publication number: 20070238779Abstract: A method of using carisoprodol comprises informing a user that administration of carisoprodol in the presence of food decreases the Cmax for carisoprodol compared to administration in the absence of food. In one embodiment, informing comprises providing printed labeling instructions. Also included are articles comprising a carisoprodol formulation and prescribing information, and methods of manufacturing carisoprodol dosage forms. Included are measures intended to increase the safe use of narrow therapeutic medications with carisoprodol.Type: ApplicationFiled: June 20, 2006Publication date: October 11, 2007Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventors: Richard H Roberts, Jie Du
-
Patent number: 7235585Abstract: This invention pertains to certain enzyme (CPG2) activated self-immolative nitrogen mustard prodrugs, which are useful in enzyme prodrug therapy (EPT), such as ADEPT and GDEPT, for the treatment of proliferative conditions, such as cancer, and which have the following formula: wherein: RN is independently C1-7alkyl; X1 is independently —I, —Br, or —Cl; X2 is independently —I, —Br, or —Cl; the group —N(CH2CH2X1)(CH2CH2X2) is independently attached at the 2-position or at the 4-position; each RG is independently —H or an ester substituent; n is independently an integer from 0 to 4; each RP, if present, is independently a phenyl substituent; m is independently an integer from 0 to 4; each RM, if present, is independently a mustard substituent; and pharmaceutically acceptable salts, solvates, amides, and esters thereof.Type: GrantFiled: September 1, 2003Date of Patent: June 26, 2007Assignee: Cancer Research Technology LimitedInventors: Caroline J. Springer, Ion Niculescu-Duvaz, Dan M. Niculescu-Duvaz
-
Patent number: 7122576Abstract: This invention is directed to a method for preventing or treating bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) or enantiomeric mixture wherein one enantiomer of Formula (I) predominates: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1–C4 alkyl; wherein C1–C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1–C4 alkyl, C1–C4 alkoxy, amino, nitro and cyano).Type: GrantFiled: February 21, 2002Date of Patent: October 17, 2006Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman, Yong Moon Choi, Robert Gordon
-
Patent number: 7115660Abstract: Angiogenesis, tumor growth, and metalloproteinase 2 (MMP2) interaction with integrin-?v?3 are inhibited by an inhibitor compound of formula (I): wherein G1 and G2 are each independently NH—C(O)—O—R1, —NH—C(O)—O—(CH2)v—(C6H4)—X3, —NH—C(O)—NH—(CH2)v—(C6H4)—X3, —O—C(O)—NH—(CH2)v—(C6H4)—X3, —O—C(O)—O—(CH2)v—(C6H4)—X3, or NH—C(O)—CH2—(C6H4)—X3; Y1 and Y2 are each independently OH, C1–C4 alkyl, C1–C4 hydroxyalkyl, C1–C4 alkoxy, phenyl, benzyl, or NH2; R1 is C1–C4 alkyl; X1 and X2 are each independently halo or C1–C4 alkoxy; X3 is halo, nitro, C1–C4 alkyl, C1–C4 alkoxy, or C1–C4 perfluoroalkyl; Z is —C?C—, —C6H4—, cis-CH?CH—, trans CH?CH—, cis-CH2—CH?CH—CH2—, trans —CH2—CH?CH—CH2—, 1,4-naphthyl, cis-1,3-cyclohexyl, trans-1, 3-cyclohexyl, cis-1,4-cyclohexyl, or trans-1,4-cyclohexyl; A is H or a covalent bond; m and n are each independently an integer having a value of 0 or 1; t is an integer having a value of 0 or 1; and p, r, and v are each independently an integer having a value of 1 or 2; with provisos that when AType: GrantFiled: March 27, 2001Date of Patent: October 3, 2006Assignee: The Scripps Research InstituteInventors: Dale L. Boger, David A. Cheresh
-
Patent number: 7087643Abstract: This invention is directed to a method for preventing or treating neuropathic pain and cluster and migraine headache-associated pain comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I): wherein phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and; R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1–C4 alkyl; wherein C1–C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of hydrogen, halogen, C1–C4 alkyl, C1–C4 alkoxy, amino, nitro and cyano).Type: GrantFiled: June 16, 2004Date of Patent: August 8, 2006Assignee: Ortho-McNeil Pharmaceutical Inc.Inventors: Ellen C. Codd, Carlos R. Plata-Salaman, Boyu Zhao
-
Patent number: 7078436Abstract: This invention is directed to a method for preventing or treating anxiety disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).Type: GrantFiled: February 21, 2002Date of Patent: July 18, 2006Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman
-
Patent number: 7056919Abstract: A wood treatment composition having a synergistic combination of fungicides which may include two or more compounds. These combinations are shown to be especially effective in providing resistance to decay, mold and mildew when wood is treated with these combinations. Also provided is wood treated by these combinations, and a method of treatment for composite wood.Type: GrantFiled: January 24, 2003Date of Patent: June 6, 2006Assignee: Kopcoat, Inc.Inventors: Alan S. Ross, Brian Marks, Hans Ward
-
Patent number: 6995283Abstract: The present invention is directed to beazophenone compounds useful in the inhibition of HIV reverse transcriptase, particularly its resistant varieties.Type: GrantFiled: February 28, 2002Date of Patent: February 7, 2006Assignee: SmithKline Beecham CorporationInventor: Joseph Howing Chan
-
Patent number: 6960571Abstract: A method of treating Restless Leg Syndrome, includes administering to a subject an iron complex having an iron release rate greater than IDI. The iron release rate is determined at a concentration of at least 2,000 ?g/dl.Type: GrantFiled: March 14, 2003Date of Patent: November 1, 2005Assignee: Luitpold Pharmaceuticals, Inc.Inventors: Mary Jane Helenek, Ralf A. Lange, Fred B. Oldham, Marc L. Tokars
-
Patent number: 6838482Abstract: The present invention provides a fungicidal composition characterized by containing as active ingredients (a) a compound represented by the formula I: (wherein Ar is a substituted or unsubstituted phenyl group, Y is an oxygen atom, an oxymethylene group or a methyleneoxy group, X is NR1R2 or OR3, and R1, R2 and R3, which may be the same or different, are hydrogen atoms or alkyl groups having 1 to 4 carbon atoms), and (b) at least one compound selected from the group consisting of ethylenebis(dithiocarbamate) type fungicidal compounds, N-(3,5-dichlorophenyl)imide type fungicidal compounds, Chlorothalonil, phthalimide type fungicidal compounds, anilide type fungicidal compounds, Cymoxanil, Fosetyl, cyanopyrrole type fungicidal compounds, anilino type heterocyclic fungicidal compounds, benzimidazole type fungicidal compounds and their precursors, sulfur, copper compounds, and carbamate type fungicidal compounds for controlling fungi tolerant to benzimidazole type fungicides.Type: GrantFiled: August 9, 2002Date of Patent: January 4, 2005Assignee: Sumitomo Chemical Company, LimitedInventor: Yukio Oguri
-
Publication number: 20040259944Abstract: This invention is directed to a method for preventing or treating neuropathic pain and cluster and migraine headache-associated pain comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I): 1Type: ApplicationFiled: June 16, 2004Publication date: December 23, 2004Inventors: Ellen C. Codd, Carlos R. Plata-Salaman, Boyu Zhao
-
Publication number: 20040248973Abstract: A wood treatment composition having a synergistic combination of fungicides which may include two or more compounds. These combinations are shown to be especially effective in providing resistance to decay, mold and mildew when wood is treated with these combinations. Also provided is wood treated by these combinations, and a method of treatment for composite wood.Type: ApplicationFiled: January 24, 2003Publication date: December 9, 2004Inventors: Alan S. Ross, Brian Marks, Hans Ward
-
Patent number: 6815557Abstract: Compounds of formula (I), in which M, A1, A2, K1 and K2 have the meanings as indicated in the description are novel active tryptase inhibitors.Type: GrantFiled: September 9, 2002Date of Patent: November 9, 2004Assignee: Altana Pharma AGInventor: Thomas Martin
-
Patent number: 6815464Abstract: This invention is directed to a method for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).Type: GrantFiled: February 21, 2002Date of Patent: November 9, 2004Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman
-
Publication number: 20040192769Abstract: Heterobifunctional polymeric prodrug platforms for delivering biologically active compounds, including proteins, monoclonal antibodies and the like are disclosed.Type: ApplicationFiled: March 21, 2003Publication date: September 30, 2004Inventors: Richard B. Greenwald, Hong Zhao
-
Publication number: 20040186061Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compouds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.Type: ApplicationFiled: January 27, 2004Publication date: September 23, 2004Applicant: Schwarz Pharma AGInventors: Claus Meese, Bengt Sparf
-
Patent number: 6790853Abstract: Competitive progesterone antagonists, including two novel steroids, viz., 11&bgr;,19-[4-(cyanophenyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11&bgr;,19-[4-(3-pyridinyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.Type: GrantFiled: March 31, 2003Date of Patent: September 14, 2004Assignee: Schering AGInventors: Krzystof Chwalisz, Walter Elger, Karin Schmidt-Gollwitzer, Eckhard Ottow
-
Publication number: 20040171679Abstract: This invention is directed to a method for preventing or treating neurodegenerative disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): 1Type: ApplicationFiled: March 10, 2004Publication date: September 2, 2004Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman
-
Publication number: 20040152770Abstract: The present invention discloses highly packed polycationic ammonium, sulfonium and phosphonium lipid compounds useful for making lipid aggregates for delivery of macromolecules and other compounds into cells. They are especially useful for the DNA-dependent transformation of cells. Methods for their preparation and use as intracellular delivery agents are also disclosed.Type: ApplicationFiled: January 21, 2004Publication date: August 5, 2004Inventors: Alberto Haces, Valentina C. Ciccarone
-
Publication number: 20040067943Abstract: Compounds of the formula (I), in which M is a central building block selected from the group below in which Al, A2, K1 and K2 are as defined in the description, are novel effective tryptase inhibitors.Type: ApplicationFiled: August 18, 2003Publication date: April 8, 2004Inventor: Thomas Martin
-
Publication number: 20040034069Abstract: A method for the inhibition of high affinity glycine transporters, compounds that inhibit these transporters; pharmaceutically active compositions comprising such compounds; and the use of such compounds either as above, or in formulations for the control or prevention of disease states in which glycine is involved are disclosed.Type: ApplicationFiled: August 8, 2003Publication date: February 19, 2004Inventors: Syed M. Ali, Kurt R. Brunden, Jack B. Jiang
-
Publication number: 20030232815Abstract: The invention relates to non-peptidic compounds that possess bioactive properties, such as the ability to protect neuronal cells from otherwise lethal treatments or the ability to promote the growth or regeneration of neuronal cells. In part, the invention provides compounds that interact with or bind to a cyclophilin and compounds that have activity towards neuronal cells. Methods for using the compounds, such as administering them to cells or animals or using them to treat neurodegenerative conditions, are specifically included.Type: ApplicationFiled: June 11, 2003Publication date: December 18, 2003Inventors: Gregory S. Hamilton, Joseph P. Steiner, Mark Vaal, Chi Choi, Ling Wei
-
Patent number: 6649591Abstract: In accordance with the present invention, there is provided a new class of drugs for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. Thus, in accordance with the present invention, dithiocarbamates are linked to the surface of a non-immunogenic, non-targeting macromolecule other than an antibody (e.g., albumin protein) either by using cross-linking reagents or by nonspecific binding to produce polydithiocarbamate-macromolecule-containing compositions, which represent a new class of drugs for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. In accordance with another aspect of the present invention, combinational therapeutic methods have been developed for the in vivo inactivation or inhibition of formation (either directly or indirectly) of species which induce the expression of inducible nitric oxide synthase, as well as reducing nitric oxide levels produced as a result of .NO synthase expression.Type: GrantFiled: October 1, 1999Date of Patent: November 18, 2003Assignee: Medinox, Inc.Inventor: Ching-San Lai
-
Patent number: 6608074Abstract: Competitive progesterone antagonists, including two novel steroids, viz., 11&bgr;,19-[4-(cyanophenyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11&bgr;,19-[4-(3-pyridinyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.Type: GrantFiled: November 28, 2001Date of Patent: August 19, 2003Assignee: Schering AGInventors: Krzystof Chwalisz, Walter Elger, Karin Schmidt-Gollwitzer, Eckhard Ottow
-
Patent number: 6599935Abstract: The present invention relates to novel felbamate derivatives and their use to treat neurological diseases such as epilepsy and to treat tissue damage resulting form ischemic events. The felbamate derivatives are modified to prevent the formation of metabolites that are believed responsible for the toxicity associated with felbamate therapy.Type: GrantFiled: December 17, 2001Date of Patent: July 29, 2003Assignee: University of Virginia Patent FoundationInventor: Timothy L. Macdonald
-
Publication number: 20030130220Abstract: The present invention provides improved ingress of therapeutic and other moieties into cellular targets. In accordance with preferred embodiments, complexes are provided which carry primary moieties, chiefly therapeutic moieties, to such target cells. Such complexes preferably feature cell surface receptor ligands to provide specificity. Such ligands are preferably bound to primary moieties through polyfunctional manifold compounds.Type: ApplicationFiled: October 31, 2002Publication date: July 10, 2003Inventor: Muthiah Manoharan
-
Patent number: 6589985Abstract: This invention is directed to a method for preventing or treating movement disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).Type: GrantFiled: February 21, 2002Date of Patent: July 8, 2003Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman
-
Patent number: 6586466Abstract: The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.Type: GrantFiled: April 20, 2001Date of Patent: July 1, 2003Assignee: SmithKline Beecham CorporationInventor: Dennis Shinji Yamashita
-
Publication number: 20030119805Abstract: The present invention provides methods and compositions comprising one or more zinc ionophores for protecting tissue from the harmful effects of apoptosis in patients in need thereof. Concentrations of zinc-pyrithione and diethyldithiocarbamate in the picomolar to nanomolar range have a strong protective effect against apoptosis.Type: ApplicationFiled: July 26, 2002Publication date: June 26, 2003Inventor: Henry Fliss
-
Publication number: 20030083372Abstract: This invention is directed to a method for preventing or treating neuropathic pain and cluster and migraine headache-associated pain comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I): 1Type: ApplicationFiled: July 11, 2002Publication date: May 1, 2003Inventors: Ellen C. Codd, Carlos R. Plata-Salaman, Boyu Zhao
-
Publication number: 20030073720Abstract: Compounds of formula (I), in which M, A1, A2, K1 and K2 have the meanings as indicated in the description are novel active tryptase inhibitors.Type: ApplicationFiled: September 9, 2002Publication date: April 17, 2003Inventor: Thomas Martin
-
Patent number: 6548540Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.Type: GrantFiled: December 12, 2000Date of Patent: April 15, 2003Assignee: Charlotte-Mecklenburg Hospital AuthorityInventor: Thomas Preston Kennedy
-
Patent number: 6545027Abstract: A method of modulating NF-kB transcription factor comprising administering to a human in need thereof an effective amount of a compound having the formula wherein R1 and R3 are independently hydrogen, wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: June 7, 1995Date of Patent: April 8, 2003Assignee: Eli Lilly and CompanyInventors: David T. Berg, David S. Calnek, Brian W. Grinnell
-
Patent number: 6541513Abstract: This invention is directed to a method for preventing or treating psychotic disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).Type: GrantFiled: February 21, 2002Date of Patent: April 1, 2003Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman
-
Patent number: 6538024Abstract: The present invention relates to novel felbamate derivatives and their use to treat neurological diseases such as epilepsy and to treat tissue damage resulting form ischemic events. The felbamate derivatives are modified to prevent the formation of metabolites that are believed responsible for the toxicity associated with felbamate therapy.Type: GrantFiled: August 9, 2001Date of Patent: March 25, 2003Assignee: University of Virginia Patent FoundationInventors: Timothy L. MacDonald, Thomas A. Miller, Charles D. Thompson, Christine M. Dieckhaus
-
Publication number: 20030055009Abstract: This invention relates to pharmaceutical compositions and methods of using non-peptidic cyclophilin-binding compounds in medical conditions involving breakdown of mitochondrial energy metabolism induced by calcium overload, in treating alopecia and promoting hair growth, in treating infections with filarial and helmintic parasites, and in treating and preventing infections with the human immunodeficiency virus.Type: ApplicationFiled: May 21, 2001Publication date: March 20, 2003Inventors: Joseph P. Steiner, Gregory S. Hamilton
-
Publication number: 20030032834Abstract: A compound of the formula [Ig]; wherein R1 is hydrogen or an amino protective group, R2 is hydrogen or hydroxy, and R3 and R4 are independently N-methyl-methoxycarbonylamino, N-ethyl-methoxycarbonylamino, N-propyl-methoxycarbonylamino or 3-ethylureid, or R3 and R4 are both methoxycarbonylamino substituted at a meta position of the benzene rings, or a salt thereof, and (2S)-1-phenoxy-3-[3,3-bis[4-methoxycarbonylamino)-phenyl]propylamino]-2-propanol sulfate (2:1) and some crystal forms thereof as &bgr;3adrenergic receptor agonists.Type: ApplicationFiled: August 19, 2002Publication date: February 13, 2003Inventors: Hiroshi Kayakiri, Naoaki Fujii, Hitoshi Hamashima, Minoru Sakurai, Kenichi Washizuka, Yasuyo Tomishima, Kiyoshi Taniguchi, Naoko Unami, Yutaka Kono, Hirofumi Ishikawa, Nobuhiro Yamamoto, Hisashi Mimura
-
Patent number: 6515019Abstract: Methods are disclosed for prophylactically and chronically preventing symptomatic depression, neuronal cell injury and cell death in systemic and neurological conditions, populations with cerebrovascular risk factors, and invasive vascular procedures, employing a glycine-site antagonist at the NMDA (N-methyl-D-aspartate) complex e.g., 2-phenyl-1,3-propanediol dicarbamate (felbamate).Type: GrantFiled: March 6, 2001Date of Patent: February 4, 2003Inventor: Walter E. Kozachuk
-
Publication number: 20020193433Abstract: This invention is directed to a method for preventing or treating bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) or enantiomeric mixture wherein one enantiomer of Formula (I) predominates: 1Type: ApplicationFiled: February 21, 2002Publication date: December 19, 2002Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman, Yong Moon Choi, Robert Gordon
-
Publication number: 20020165273Abstract: This invention is directed to a method for preventing or treating neurodegenerative disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): 1Type: ApplicationFiled: February 21, 2002Publication date: November 7, 2002Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman
-
Publication number: 20020165272Abstract: This invention is directed to a method for preventing or treating psychotic disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): 1Type: ApplicationFiled: February 21, 2002Publication date: November 7, 2002Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman
-
Publication number: 20020161038Abstract: The present invention relates to novel compounds, methods of preparing these compounds, and pharmaceutical compositions comprising these compounds. These compounds are carbamate prodrugs that convert to active inhibitors of the IMPDH enzyme in vivo. The compounds and pharmaceutical compositions of this invention are particularly well suited for activation and subsequent inhibition of the IMPDH enzyme activity. Consequently, these prodrugs may be advantageously used as therapeutic agents for IMPDH mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds and compositions of this invention.Type: ApplicationFiled: April 17, 2002Publication date: October 31, 2002Inventors: Dean P. Stamos, Randy S. Bethiel
-
Publication number: 20020156070Abstract: The present invention relates to novel felbamate derivatives and their use to treat neurological diseases such as epilepsy and to treat tissue damage resulting form ischemic events. The felbamate derivatives are modified to prevent the formation of metabolites that are believed responsible for the toxicity associated with felbamate therapy.Type: ApplicationFiled: December 17, 2001Publication date: October 24, 2002Inventor: Timothy L. Macdonald
-
Publication number: 20020156127Abstract: This invention is directed to a method for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): 1Type: ApplicationFiled: February 21, 2002Publication date: October 24, 2002Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman
-
Publication number: 20020151585Abstract: This invention is directed to a method for preventing or treating movement disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): 1Type: ApplicationFiled: February 21, 2002Publication date: October 17, 2002Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman
-
Publication number: 20020143053Abstract: This invention is directed to a method for preventing or treating anxiety disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): 1Type: ApplicationFiled: February 21, 2002Publication date: October 3, 2002Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman
-
Patent number: RE38915Abstract: Modulation of the activity of the insulin receptor, enhancement of glucose uptake by cells, and other effects significant in the control and management of diabetes are accomplished using compounds of the formula wherein each A is independently a proton-accepting substituent; each R is independently a noninterfering substituent; n is 0, 1, or 2; and each linker is independently an isostere of —NHCONH— or of —N?N— or of —NHCO—. Compounds in the genus of Formula (1) can also be used for structure activity studies to identify features responsible for the relevant activities.Type: GrantFiled: December 21, 2000Date of Patent: December 6, 2005Assignee: Telik, Inc.Inventors: Richard Sportsman, Hugo O. Villar, Lawrence M. Kauvar, Wayne R. Spevak